• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.70%

    Endo International plc (ENDP)

    -NasdaqGS
    15.31 Down 0.13(0.84%) May 25, 4:00PM EDT
    |After Hours : 15.25 Down 0.06 (0.39%) May 25, 7:47PM EDT
    ProfileGet Profile for:
    Endo International plc
    Minerva House
    Simmonscourt Road
    Dublin, 4
    Ireland - Map
    Phone: 353 1 268 2000
    Website: http://www.endo.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Other
    Full Time Employees:6,406

    Business Summary 

    Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain management products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, as well as XIAFLEX for treating Peyronie’s and Dupuytren’s contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, as well as Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The company’s U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, women’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc is headquartered in Dublin, Ireland.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Endo International plc

    Corporate Governance 
    Endo International plc’s ISS Governance QuickScore as of May 1, 2016 is 10. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Rajiv Kanishka Liyanaarchchie De Silva , 49
    Chief Exec. Officer, Pres and Director
    2.84M0.00
    Mr. Suketu P. Upadhyay , 47
    Chief Financial Officer and Exec. VP
    1.33M0.00
    Dr. Susan T. Hall Ph.D., 56
    Chief Scientific Officer, Global Head of R&D & Quality and Exec. VP
    1.08M0.00
    Mr. Matthew Joseph Maletta , 44
    Chief Legal Officer and Exec. VP
    749.00K0.00
    Mr. Paul V. Campanelli , 54
    Pres of Par Pharmaceutical
    1.34M0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders